From: Long-term cardiac effects of modern treatment for Hodgkin’s lymphoma
AC + MRT (n = 132) | AC alone (n = 114) | Controls (n = 58) | p-value (ANOVA) | p-value AC + MRT vs. AC alone | p-value AC + MRT vs. controls | p-value AC alone vs. controls | |
---|---|---|---|---|---|---|---|
Morphology | |||||||
LA volume, mL/m2 | 25 ± 6 | 27 ± 8 | 29 ± 7 | 0.016 | 0.56 | 0.012 | 0.31 |
IVSd, mm | 8.8 ± 2.0 | 9.1 ± 1.8 | 9.2 ± 1.8 | 0.33 | 0.74 | 0.57 | 1.00 |
LVIDd, mm | 47 ± 6 | 50 ± 5 | 49 ± 6 | < 0.001 | < 0.001 | 0.027 | 0.92 |
LVPWd, mm | 7.8 ± 1.4 | 8.2 ± 1.3 | 8.3 ± 1.4 | 0.012 | 0.043 | 0.035 | 1.00 |
LV Mass, g/m2 | 67 ± 17 | 76 ± 18 | 76 ± 18 | 0.002 | 0.004 | 0.013 | 1.00 |
3D LV EDV, mL/m2 | 60 ± 9 | 64 ± 10 | 65 ± 10 | 0.012 | 0.09 | 0.015 | 1.00 |
3D LV ESV, mL/m2 | 25 ± 6 | 28 ± 6 | 27 ± 5 | 0.06 | 0.06 | 0.45 | 1.00 |
RA area, cm2/m2 | 16 ± 3 | 17 ± 3 | 17 ± 3 | 0.06 | 0.15 | 0.14 | 1.00 |
RV end-diastolic area, cm2/m2 | 9.3 ± 1.5 | 9.6 ± 1.7 | 9.9 ± 1.6 | 0.18 | 0.05 | 0.34 | 1.00 |
RV end-systolic area, cm2/m2 | 5.6 ± 1.1 | 6.0 ± 1.1 | 5.8 ± 1.0 | 0.11 | 0.020 | 0.85 | 0.29 |
Systolic function | |||||||
3D LV EF, % | 58 ± 5 | 57 ± 5 | 59 ± 4 | 0.13 | 1.00 | 0.32 | 0.15 |
3D LV SI, mL/m2 | 35 ± 5 | 36 ± 6 | 39 ± 6 | 0.004 | 0.49 | 0.002 | 0.14 |
LV GLS, % | 19.3 ± 2.5 | 20.2 ± 2.6 | 20.8 ± 2.0 | < 0.001 | 0.034 | < 0.001 | 0.34 |
RV FAC, % | 40 ± 7 | 39 ± 6 | 41 ± 7 | 0.28 | 0.81 | 1.00 | 0.39 |
TAPSE, mm | 22 ± 3 | 22 ± 3 | 24 ± 3 | 0.001 | 1.00 | 0.002 | 0.004 |
Diastolic function | |||||||
Mitral E velocity, cm/sec | 67 ± 18 | 63 ± 15 | 65 ± 14 | 0.13 | 0.13 | 1.00 | 1.00 |
Mitral A velocity, cm/sec | 60 ± 16 | 54 ± 14 | 51 ± 15 | < 0.001 | 0.18 | 0.001 | 0.56 |
Mitral E/A-ratio | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.4 ± 0.4 | 0.009 | 0.92 | 0.007 | 0.08 |
Mitral DT, ms | 175 ± 47 | 187 ± 52 | 161 ± 46 | 0.005 | 0.22 | 0.22 | 0.004 |
E/e’-ratio | 7.7 ± 2.4 | 7.1 ± 2.8 | 6.9 ± 1.8 | 0.06 | 0.20 | 0.11 | 1.00 |
TR velocity, m/s | 23 ± 3 | 23 ± 3 | 23 ± 2 | 0.99 | 1.00 | 1.00 | 1.00 |